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Abstract
Inhibition of cathepsin L (Cat L) can be considered a target for COVID-19 treatment. Starchytapheta jamaicensis is a
plant from the Verbenaceae family that is commonly used for medicinal purposes. This study aims to analyze the
inhibitory activities of compounds of Stachytarpheta jamaicensis toward Cat L by computational docking analysis. Ten
compounds contained in the extracts (i.e., α-spinasterol, apigenin, luteolol-7-glucuronide, friedelin, hispidulin, chlorogenic
acid, ipolamiide, geraniol, hentriacontane, and γ-aminobutyric acid) were selected as ligands; decanoyl-arg-val-lys-argchloromethylketone and oxocarbazate were used as the reference. Computational docking analysis was performed using
Autodock Vina integrated into PyRx 8.0 and visualized using the Discovery Studio Visualizer v19.1.0.18287 (2019 version)
based on the scoring functions. Seven bioactive compounds were bound more strongly than decanoyl-arg-val-lys-argchloromethylketone: α-spinasterol, apigenin, luteolol-7-glucuronide, friedelin, hispidulin, chlorogenic acid, and ipolamiide.
However, all bioactive compounds were bound with less strength than oxocarbazate. Apigenin showed the best affinity,
with much hydrogen bonding, and had the same ASN18 residue as Cat L inhibitor 1. Pre ADMET showed that all
compounds of S. jamaicensis did not have hepatotoxicity, mutagenic, and carcinogenic criteria. The current research
indicates that S. jamaicensis compounds can be used as an inhibitor for Cat L and as a COVID-19 drug candidate.
Keywords: active compounds, cathepsin L, COVID-19, SARS-CoV2, Stachytarpheta jamaicensis

host cell invasion mediated by the spike (S) glycoprotein.
Protein S is a glycosylated type 1 membrane protein consisting of S1 and S2 subunits. The N-terminal S1 subunit consists of a receptor-binding domain that mediates
binding to host cell receptors, namely, ACE2 for SARSCoV and SARS-CoV-2 [6].

Introduction
COVID-19 is an acute respiratory disease caused by a
coronavirus (SARS-CoV-2) transmitted from animals to
humans [1]. Viruses enter the human body through the
respiratory system. The spike protein on the SARS-CoV-2
viral membrane interacts with the angiotensin-converting
enzyme (ACE2) receptor to enter the host cells on the target cell surface [1, 2]. SARS-CoV-2 infection has a similar transmission mechanism to SARS-CoV [3]. SARSCoV, mediated by protein S, increases the sensitivity
to protease inhibitors, namely, leupeptin [4]. The potential targets of SARS-CoV antivirals can be divided into
two categories: the target of the action, which is the human immune system or human cells, and the coronavirus
itself [5]. Other compounds are usually attached to several cell receptors in the human immune system that can
block the attachment between the SARS-CoV virus and
target cells. The first step of SARS-CoV-2 infection is

SARS-CoV-2 uses ACE2 for entry and the serine protease
TMPRSS2 for S protein priming [7]. SARS-CoV-2 entry
has three stages: membrane fusion involving receptor
binding, inducing a change in the shape of the S glycoprotein, activation of cathepsin L, and activation of membrane fusion through the endosome [4, 8]. Cathepsin L will
mediate the cleavage of the spike glycoprotein S1 subunit
on the surface of the coronavirus. The coronavirus requires this division to enter the human host cell. Next, the
endosome membrane of the host cell and the virus will
fuse, and then the viral RNA releases the next stage of
replication. A cell-free membrane-fusion system exhibits
25
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receptor binding followed by proteolysis, the action of
cathepsin L [4].
Cathepsin L (Cat L) is one type of endosomal cysteine
protease enzyme that assembles collagen from procollagen
and plays a role in cell proliferation, namely, proteolytic
control by cyclins [9]. In addition, this enzyme plays a
role in physiological processes such as cell-matrix degradation in the inflammatory process, apoptosis, antigen
processing, and MHC class II immune responses [10–12].
Elastolytic cysteine proteases are mobilized to the cell
surface of macrophages and other cells under inflammatory conditions, which leads to accelerated collagen and
elastin degradation, exacerbating inflammation and tissue damage [11, 12]. Cathepsin requires pH conditions between 4.5–5, which describe the state of lysosomes. The
expression of this enzyme is usually expressed in various
cell types and all tissues. It plays an essential role in the
proteolysis of antigen proteins caused by the endocytosis
of pathogens [9]. Previous studies showed inhibition of
Cat L overexpression in SARS-CoV-2 pseudo-virus infection by administering Cat L inhibitors in vitro and in
vivo [13, 14]. Thus, inhibition of Cat L can be considered
a target for COVID-19 treatment. In silico molecular
docking is used to predict the interaction between ligands (small molecules) and large molecules, such as proteins, enzymes, and carbohydrates, to predict the exchange's stability and spontaneity, which can be seen
through the smaller free energy [15,16]. Molecular docking is often used to discover new drug candidates and
study antigen and antibody interactions. Additionally, molecular docking is often used to find potential compounds that can act as work inhibitors of disease agents,
such as viruses and bacteria [17, 18].
Throughout human history, herb species and fruits have
served as sources of herbal medicine. They contain various phytochemicals, such as flavonoids, alkaloids, glucosides, and polyphenolic compounds. Secondary metabolites found in S. jamaicensis have a role as anti-cancer,
anti-allergy, antioxidant, and anti-inflammatory agents
and as an inhibitor of certain enzymes [19–21]. S. jamaicensis also has been used as a traditional medicine to
cure allergies and problems with respiratory conditions,
coughs, colds, fever, and digestive complications [22].
S. jamaicensis is a plant from the Verbenaceae family
that grows in the tropics. Almost all parts of this plant can
be used as medicine [23]. In general, the people of Kalimantan use this plant to treat sore throats and coughs.
According to Liew (2015), S. jamaicensis contains secondary metabolites, such as flavonoids, phenols, saponins, tannins, and terpenoids [22].
S. jamaicensis contains glycosides, which are usually
found only in Verbenaceae plants. In previous studies,
Stachytarpheta species phytochemical screening revealed
the presence of alkaloids, tannins, saponins, glycosides,
Makara J. Sci.

steroids, and phenols [24–26]. The main plant chemicals
in S. jamaicensis include apigenin-7-glucuronide, α-spinasterol, γ-aminobutyric acid, chlorogenic acid, citral, dopamine, friedelin, geraniol, hentriacontane, hispidulin,
ipolamiide, luteolol-7-glucuronide, n-dotriacontane, nnonacosane, n-pentriacontane, n-tetratriancontane, n-triacontane, n-tritriacontane, salicylic-acid, scutellarein,
stachytarphine, stigmasterol, tarphetalin, ursolic acid,
and verbascoside [27]. Lipinski's rule of five is used to
predict the oral bioavailability of a drug-likeness of these
compounds [28]. All compounds used in this simulation,
namely, α-spinasterol, apigenin, luteolin-7-glucuronide,
friedelin, hispidulin, chlorogenic acid, ipolamiide, geraniol,
hentriacontane, and γ-aminobutyric acid, complied with
Lipinski’s rule.
The comparison ligands used in this study are inhibitor
compounds that act directly on Cat L, namely, decanoylarg-val-lys-arg-chloromethyl ketone (Ddec-RVKRCMK) and oxocarbazate [29–31]. This study predicts a
therapeutic target for SARS-CoV-2 using 10 compounds
from Stachytarpheta jamaicensis that may inhibit novel
coronaviruses through cathepshin L inhibition and provides scientists with information on compounds that may
be effective.

Methods
Data mining/ligand and protein sampling. The molecular docking receptor preparation 3D structure of Cat L
(3K24) was taken from the Protein Data Bank
(https://www.rcsb.org/). The preparation structure of the
bioactive compound of S. jamaicensis and 3D structures
of the ligand references (Ddec-RVKR-CMK and oxocarbazate) were downloaded from PubChem
(https://pubchem.ncbi.nlm.nih.gov/). Protein structures
were downloaded in.pdb format, while ligands were
downloaded in SDF format.
Protein and ligand preparation. The compounds used
were apigenol-7-glucuronide (CID 5319484), α-spinasterol
(CID 5281331), γ-aminobutyric acid (CID 119), chlorogenic acid (CID 1794427), friedelin (CID 91472), geraniol (CID 637566), hentriacontane (CID 12410), hispidulin (CID 5281628), ipolamiide (CID 442425), and
luteolol-7-glucuronide (CID 5280601). Molecular docking proteins were prepared using Discovery Studio version 16 (Dassault Systèmes BIOVIA, 2015) to remove
previously attached ligands, while ligands were prepared
using Open Babel integrated into PyRx 8.0 (Dallakyan &
Olson, 2015) to minimize their energy and convert them
to.pdb format [32].
Docking method validation. The docking method was
validated by the redocking method using a natural ligand
(2-acetamido-2-deoxy-beta-D-glucopyranose) (CID:
24139) with the prepared cathepsin L receptor [33]. In the
docking validation process, the parameter is the RMSD
March 2022  Vol. 26  No. 1
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(root mean square deviation) value. The results of validating the native ligand with the cathepsin L receptor
showed an RMSD value of 1.784 Å. The RMSD describes how much the protein–ligand interaction changes
during docking to determine the deviation value. The
docking method is valid if the value of RMSD ≤ 2 Å,
which means that the docking parameter is valid, so that
the docking method can be used to dock the test compound. This result showed that the docking method was
valid and the setting parameters were validation criteria,
so these parameters can be used for docking the test compound.
Docking of the protein–ligand and visualization. A
molecular docking simulation was performed using Autodock Vina integrated into PyRx 8.0. Virtual prediction
analysis and visualization of protein–ligand complexes
from the docking step were analyzed and visualized using
Discovery Studio. The interaction site was analyzed
based on the ligand–residue interaction and structural
conformation. Cat L was also docked with reference ligands to compare the binding affinity of the 10 active compounds used in this study according to previous research.
Drug-likeness, pharmacokinetic, and safety predictions. Lipinski’s rule of 5 was used to predict the druglikeness of bioactive compounds, which is evaluated by
the free accessible website www.molinspiration.com. The
pharmacokinetic and safety predictions were performed
using a special program at http://biosig.unimelb.edu.au/
pkcsm/. The pharmacokinetic parameters included absorption, distribution, and excretion.
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Results and Discussion
Table 1 compares the physicochemical properties of the
S. jamaicensis bioactive compounds with two native ligands. According to Lipinski’s rule of 5, α-spinasterol, γaminobutyric acid, hispidulin, geraniol, friedelin, and
hentriacontane are predicted to be favorable oral drug
candidates because they have a molecular weight of less
than 500, fewer than five hydrogen bond donors, and
fewer than 10 hydrogen bond acceptors. However, according to the logP value, α-spinasterol, hispidulin, geraniol, friedelin, and hentriacontane are more complimentary because of their solubility in the aqueous phase.
According to the pharmacokinetic prediction (Table 2),
most of the bioactive compounds of S. jamaicensis are
well-absorbed in the human intestine, as the range of absorption was 70–100%, excluding apigenin, chlorogenic
acid, luteolin, and ipolamiide. The highest absorbed compounds in Caco-2 cells were friedelin and α-spinasterol,
at 1.27 and 1.21 log cm/s, respectively. The Caco-2 cells
are an in vitro model for determining drug transport
through intestinal epithelium derived from human colonic
adenocarcinomas that have multiple transport pathways
[34]. The data show that the permeability of the active
compound to pass through the intestinal epithelium is still
relatively small. This attribute can affect its bioavailability in the blood, so pharmaceutical or structural modification must be performed to increase the permeability
properties of these compounds.

Table 1. Physicochemical Properties of S. jamaicensis Bioactive Compounds in Correlated with Lipinski’s Rules

No

Ligand

Molecular
Weight
(g/mol)

logP

Hydrogen Hydrogen
Molar RefracBond Donor Bond Activity
(n)
ceptor (n)

744.42

0.77

9

8

203.46

288.29

535.60

3.34

4

6

147.85

141.86

TPSA

2

Decanoyl-arg-val-lys-argchloromethylketone
Oxocarbazate

3

Apigenin-7-glucuronide

446.40

0.14

6

10

106.72

178.47

4

α-Spinasterol

412.70

7.80

1

1

132.75

186.35

5

γ-Aminobutyric acid

103.12

−0.19

2

2

25.82

63.32

6

Chlorogenic acid

354.31

−0.65

6

8

83.50

164.75

7

Hispidulin

300.26

2.58

3

6

80.48

100.13

8

Luteolol-7-glucuronide

462.40

−0.15

7

11

108.74

207.35

9

Geraniol

154.25

2.67

1

1

50.40

20.23

10 Friedelin

426.70

8.46

0

1

134.39

17.07

11 Ipolamiide

406.40

−2.89

6

11

88.60

175.37

12 Hentriacontane

436.80

12.30

0

0

151.13

0.00

1

Table 2. Pharmacokinetic Prediction of S. jamaicensis Bioactive Compounds by ADMET
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No.

Ligand

Caco-2
(nm.sec-1)

Human
intestinal
absorption (%)

VDss
(log
L/kg)

CYP2D6
Inhibitor

Total Clearance (log
mL/min/kg)

1

Decanoyl-arg-val-lys-arg-chloromethylketone

0.35

8.62

−0.74

No

0.32

2

Oxocarbazate

0.25

70.64

−0.35

No

−0.02

3

Apigenin-7-glucuronide

−0.69

15.26

0.32

No

0.59

4

α-Spinasterol

1.21

94.97

0.77

No

0.61

5

γ-Aminobutyric acid

0.58

77.81

−0.65

No

0.57

6

Chlorogenic acid

−0.84

36.38

0.58

No

0.31

7

Hispidulin

−0.04

84.65

0.37

No

0.53

8

Luteolol-7-glucuronide

−0.89

15.20

0.86

No

0.52

9

Geraniol

1.49

92.79

0.17

No

0.44

10

Friedelin

1.27

98.74

−0.27

No

−0.04

11

Ipolamiide

0.43

27.52

0.18

No

1.27

12

Hentriacontane

1.10

85.89

−0.02

No

2.19

According to the pharmacokinetic prediction (Table 2),
most of the bioactive compounds of S. jamaicensis are
well-absorbed in the human intestine, as the range of
absorption was 70–100%, excluding apigenin,
chlorogenic acid, luteolin, and ipolamiide. The highest
absorbed compounds in Caco-2 cells were friedelin and
α-spinasterol, at 1.27 and 1.21 log cm/s, respectively. The
Caco-2 cells are an in vitro model for determining drug
transport through intestinal epithelium derived from
human colonic adenocarcinomas that have multiple
transport pathways [34]. The data show that the
permeability of the active compound to pass through the
intestinal epithelium is still relatively small. This
attribute can affect its bioavailability in the blood, so
pharmaceutical or structural modification must be
performed to increase the permeability properties of
these compounds.
The distribution phases, the second phase of
pharmacokinetics, may interact with each other, known
by the volume of distribution (VDss). α-Spinastrol and
luteolol-7-glucuronide had a range of VDss values
(between 0.71 L/kg and 2.81 L/kg), which were higher
than those of other compounds. Many drugs are bound to
proteins in the plasma and make an ineffective form, and
the free plasma concentration of a drug is active. A
balancing between bound and unbound forms of a drug
occurs. When free unbound drugs are excreted, some

drugs displace other drugs from their proteins, increasing
the free, unbound concentration in the plasma, which
leads to side effects [35]. The VDss considers seeing the
potential toxicity of a drug. The third drug
pharmacokinetics phase is hepatic metabolism. Almost
all available drugs are metabolized by CYP450 enzymes
[36]. This study showed that all compounds have no
inhibition against the CYP450 enzyme, thus the
pharmacokinetics prediction was enzymatic.
A safety prediction of all bioactive compounds was made
by determining the acute and chronic lethal dosages as
LD50 and LOAEL, respectively (Table 3). A toxicity
prediction demonstrated that apigenin, α-spinasterol,
luteolin, and friedelin have a higher LD50 than the
reference ligand compound. Prediction of toxicity
through the same site, using the Ames test method, is a
simple way to test the properties of compounds in the
form of mutagenic and carcinogenic properties as
frameshift mutagens [37,38]. The prediction result data
indicate that all active compounds of S. jamaicensis are
neither mutagenic nor carcinogenic. Likewise, the
hepatoxicity test results showed that none of the ligands
of the active compound S. jamaicensis induced liver
damage. However, the hepatotoxicity results indicate that
the reference ligand compound has the potential to cause
liver damage, so the toxicity data of the tested ligand are
better than those of the reference ligand.

Table 3. Toxicity and Safety Predictions of S. jamaicensis Compounds and Reference Ligands by ADMET
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No.
1
2
3
4
5
6
7
8
9
10
11
12

Ligand
Decanoyl-arg-val-lys-arg-chloromethylketone
Oxocarbazate
Apigenin-7-glucuronide
α-Spinasterol
γ-Aminobutyric acid
Chlorogenic acid
Hispidulin
Luteolol-7-glucuronide
Geraniol
Friedelin
Ipolamiide
Hentriacontane

Oral Rat Acute Tox- Oral Rat Chronic
icity (LD50)
Toxicity (LOAEL)
(mol/kg)
(log mg/kg_bw/day)

AMES
toxicity

Hepatotoxicity

No

Yes

2.48

2.82

No
No
No
No
No
No
No
No
No
No
No

Yes
No
No
No
No
No
No
No
No
No
No

2.37
2.64
2.54
1.64
1.97
2.40
2.56
1.64
2.64
2.23
1.86

3.70
4.40
0.87
2.93
2.98
1.63
4.30
2.03
0.91
3.42
0.85

Table 4 shows the binding capacity of S. Jamaicensis
bioactive compounds on Cat L as an enzyme related to
the COVID-19 cycle in humans. The binding energy of
the 10 bioactive compounds varied from −4.2 to −8.9
kcal/mol. Seven bioactive compounds were more strongly
bound than decanoyl-arg-val-lys-arg-chloromethyl ketone
as an inhibitor of Cat L, namely, α-spinasterol, apigeninand luteolol-7-glucuronide, friedelin, hispidulin,
chlorogenic acid, and ipolamiide. However, all the
bioactive compounds were less strongly bound than
oxocarbazate as the second inhibitor of Cat L. The
binding interaction value has the potential to predict the
interaction strength between ligand and receptor, as a
more negative value indicates a stronger binding
interaction [32]. The energy values provide an
approximate estimate of the ease of formation, the relief
of disruption, and the relative strengths of various
intermolecular interaction types [39].
Although the bioactive compounds of S. jamaicensis have a weaker binding interaction than oxocarbazate,
geraniol has the most similar hydrogen bond interaction
with oxocarbazate at residues PRO15, ARG8, and
VAL13. A less similar interaction was demonstrated between oxocarbazate and chlorogenic acid, followed by
hentriacontane and hispidulin. Meanwhile, the bioactive
compounds of apigenin, α-spinasterol, chlorogenic acid,
hispidulin, and luteolol-7-glucoronide have one hydrogen bond interaction similar with decanoyl-arg-val-lysarg-chloromethylketone.
Hydrogen bonding is a principle protein–ligand interaction. This bond provides stronger affinity, thus it is crucial in drug design development [40]. Intramolecular hydrogen bonds have considerable importance in stabilizing
structures [39]. Hispidulin was the compound ligand and
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Cat L complex with the most hydrogen bonds. Meanwhile, hentriacontane had the most hydrophobic bonds.
Hydrophobic binding plays a vital role in stabilizing the
conformation of proteins, transporting lipids by plasma
proteins, and binding steroids to their receptors, among
other examples [39].
Apigenin–Cat L complex interactions were through carbon-hydrogen bonds, conventional hydrogen bonds, pi-pi
stacking, and pi-alkyl formation. The binding energy of the
apigenin–Cat L complex was −8.7 kcal/mol. The docking
energy generated from the interaction between α-spinasterol and Cat L was −8.9 kcal/mol. Six bonds were
formed in this interaction (Figure 1d). Hydrogen bonds
occurred at GLU148 and GLU192 on the OH groups of
ligand molecules. Hydrophobic bonds involved HIS163,
TRP189, and TRP193.
γ-Aminobutyric acid was observed to bind to the Cat L
site with −4.2 kcal/mol (Figure 1e). The γ-aminobutyric
acid–Cat L complex had weaker interactions than the
complexes of other ligands (Table 2). On the basis of the
molecular docking results shown in Table 2, amino acid
residues bonded to γ-aminobutyric acid through conventional hydrogen bonds.
The chlorogenic acid–Cat L complex had more interactions than the complexes of γ-aminobutyric, geraniol,
ipolamiide, and hetriacontane based on the molecular
docking results shown in Figure 1. There are three hydrogen bonds between the chlorogenic acid ligand and Cat L
and a −8.2 kcal/mol binding energy with ARG8,
TYR198, and GLU191. Conversely, PRO15, ARG8, and
VAL13 mediated pi-alkyl and amide pi-stacking through
hydrophobic interactions. The amino acid residue VAL13
interacted with this ligand through other bonds.

Table 4. Comparison of the Binding Energy of Compound Ligands and Reference Ligands with Cat L
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Hydrogen Bond Interaction
Compound

Amino residues
(Interaction Type)

Distance (Å)

−5.6

GLU192 (Electrostatic)
TYR182 (Conventional)
ASN18 (Conventional)
GLU191 (Conventional)
TYR170 (Conventional)
TYR182 (Conventional)
ASP6 (Conventional)
GLU9 (Conventional)
GLU50 (Conventional)
GLU86 (Conventional)
PHE172 (Pi-Alkyl)

4.3
2.3
2.9
2.4
3.07
2.7
2.5
3.04
3.03
2.9
4.9

−11

ASP6 (Attractive)
GLU9 (Attractive)
GLU191 (Conventional)
VAL16 (Conventional)
TYR182 (Pi-Donor)
ARG8 (Alkyl)
ARG8 (Alkyl)
PRO15 (Alkyl)
PRO15 (Alkyl)
VAL13 (Alkyl)
LEU184 (Alkyl)

4.5
4.7
2.5
2.9
3.9
4.8
4.7
4.5
5.02
5.4
5.3

−8.7

GLN19 (Conventional)
ASP162 (Conventional)
ASN18 (Conventional)
LEU144 (Conventional)
GLY23 (Carbon)
TRP 189 (Pi-Pi Stacked)
LEU144 (Pi-Alkyl)

2.8
2.4
2.3
2.6
3.4
3.5
5.04

−8.9

GLU148 (Conventional)
GLU192 (Conventional)
TRP189 (Pi-Sigma)
HIS163 (Pi-Alkyl)
TRP189 (Pi-Alkyl)
TRP193 (Pi-Alkyl)

2.6
2.4
3.6
5.04
3.7
5.3

−4.2

GLY196 (Conventional)
GLU192 (Conventional)
TRP193 (Conventional)
GLY194 (Conventional)
LYS147 (Conventional)

3.01
2.6
2.4
2.1
2.3

Docking Score (kcal/mol)

Decanoyl-arg-val-lys-argchloromethylketone (Ddec-RVKRCMK)
(Inhibitor 1)

Oxocarbazate (Inhibitor 2)

Apigenin-7-glucuronide

α-Spinasterol

γ-Aminobutyric acid

Table 4. Comparison of the Binding Energy of Compound Ligands and Reference Ligands with Cat L (Continue)
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Hydrogen Bond Interaction
Compound

Docking Score (kcal/mol)
−8.2

Chlorogenic acid

2.8
2.7
2.1
3.3
2.9
4.9
3.7
5.02
5.3

ARG8 (Conventional)
GLY191 (Conventional)
GLU191 (Conventional)
MET195 (Carbon)
GLY196 (Carbon)
THR14 (Amide Pi-Stacked)
TYR198 (Conventional)
PRO15 (Pi-Alkyl)
VAL16 (Pi-Alkyl)
ARG8 (Pi-Alkyl)
VAL13 (Pi-Alkyl)

2.9
2.4
2.1
3.3
3.5
4.7
4.9
3.6
5.02
4.8
5.3

−8.7

GLY164 (Conventional)
ASN18 (Conventional)
HIS163 (Carbon)
ASP162 (Carbon)
TRP189 (Pi- Pi Stacked)

3.25
1.86
3.2
3.3
3.9

−5.5

MET195 (Conventional)
GLY196 (Carbon)
PRO15 (Alkyl)
ARG8 (Alkyl)
VAL13 (Alkyl)

2.4
3.3
4.8
3.8
4.4

−8.7

LYS147 (Conventional)

2.9

−7.3

GLN19 (Conventional)
TRP26 (Conventional)
GLY164 (Conventional)
GLY68 (Conventional)
TRP26 (Carbon)

3.3
3.3
3.2
2.4
3.5

−4.3

PRO90 (Alkyl)
LYS17 (Alkyl)
VAL5 (Alkyl)
LYS10 (Alkyl)
PRO15 (Alkyl)
TYR91 (Alkyl)

5.4
3.7
4
4.9
3.9
4.9

Luteolol-7-glucuronide

Geraniol

Ipolamiide

Hentriacontane

Three conventional hydrogen bonds and two carbon-hydrogen bonds were formed between hispidulin and Cat L
protein (Figure 1g). The amino acid residues involved in
hydrogen bond formation were ARG8, GLY191,
Makara J. Sci.

Distance (Å)

−8.6

Hispidulin

Friedelin

Amino residues
(Interaction Type)
ARG8 (Conventional)
TYR198 (Conventional)
GLU191 (Conventional)
ARG8 (Carbon)
VAL13 (Pi Lone Pair)
THR14 (Amide Pi-Stacked)
PRO15 (Pi-Alkyl)
ARG8 (Pi-Alkyl)
VAL13 (Pi-Alkyl)

GLU191, MET195, and GLY196. Six amino acid residues, namely, THR14, TYR198, PRO15, VAL16,
ARG8, and VAL13, formed hydrophobic interactions
with hispidulin. The binding energy of the hispidulin–Cat
March 2022  Vol. 26  No. 1
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L complex was −8.6 kcal/mol. The luteolol-7-glucuronide–Cat L complex and friedelin–Cat L complex had
slightly more interactions than the hispidulin–Cat L complex, resulting in a −8.7 kcal/mol binding energy (Table
4). On the basis of the molecular docking results shown
in Figure 1h, GLY164, ASN18, HIS163, and ASP162
formed hydrogen bonds with luteolin. Only TRP189 interacted with luteolin through pi-pi stacked hydrophobic
bonds (Figure 1h ). In comparison, only LYS147 of the
friedelin–Cat L complex had a conventional hydrogen
bond (Figure 1j). Five interactions were facilitated by
carbon-hydrogen bonding, conventional hydrogen bonding, and alkyl formation in the geraniol-Cat L complex
shown in Figure 1i. Two hydrogen bonds were formed by
MET195 (conventional) and GLY196 (carbon). PRO15,
ARG8, and VAL13 formed hydrophobic bonds. The
binding energy of this complex was −5.5 kcal/mol.
The binding energy of the ipolamiide–Cat L complex was
−7.3 kcal/mol, higher than the complexes of geraniol, γaminobutyric, hentriacontane, and inhibitor 1. GLN19,
TRP26, GLY164, GLY68, and TRP 26 interacted with
ipolamiide through conventional hydrogen bonds and
carbon-hydrogen bonds (Figure 1k). The last docking

compound of S. jamaicensis was hentriacontane. This ligand had a −4.3 kcal/mol binding energy, which was similar to the γ-aminobutyric binding energy (Table 1), despite differences in amino acid residues. The hentriacontane-Cat L complex had six amino residues, namely,
PRO90, LYS17, VAL5, LYS10, PRO15, and TYR91.
They bonded to hentriacontane through alkyl hydrophobic bonds (Figure 1l).
Although α-spinasterol had the highest binding energy, it
did not have the same amino acid residues as inhibitor 1
and inhibitor 2. Among all compounds, apigenin showed
the best affinity, with many hydrogen bonds, and it had
the same ASN18 residue as inhibitor 1 of Cat L. Apigenin's affinity and interaction with Cat L was even better
than that of inhibitor 1. α-Spinasterol had the highest
binding energy, and its amino acid residues differed from
those of inhibitor 1 and inhibitor 2. Among all the tested
S. jamaicensis compounds, apigenin showed the best affinity, with many hydrogen bonds, and had the same
ASN18 residue as the Cat L inhibitor 1. Apigenin’s affinity and interaction with Cat L was even better than that
of inhibitor 1.

A. Cat L- Decanoyl-arg-val-lys-arg-chloromethylketone

B. Cat L- Oxocarbazate

C. Cat L-Apigenin

D. Cat L- Sitosterol
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E. Cat L- Butyric acid

F. Cat L-Chlorogenic acid

G. Cat L-Hispidulin

H. Cat L-Luteolol
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I. Cat L-Geraniol

J. Cat L-Friedelin

K. Cat L-Ipolamiide

L. Cat L-Hentriacontane

Figure 1. 3D Structures of the Interaction between S. jamaicensis Compounds (Turquoise) and the Cat L Receptor (Purple –
Fuschia). Left and Center Sides Show the 3D Structure of the Interaction, While the Coded Right Side is the 2D
Interaction and Category Bond of the Complex. Molecular Docking was Performed using Pyrx 8.0.0 Software and
Visualization was Analyzed by the Discovery Studio Visualizer v19.1.0.18287 Program

Conclusion
In silico molecular docking studies obtained the models
of the interactions between the ligands and the cathepsin
L protein. The interactions between this protein and the
ligands used in this study help us to understand the
potential mechanisms of their interactions. Most of the
bioactive compounds of S. jamaicensis were predicted to
be well-absorbed in the human intestine, excluding
apigenin, chlorogenic acid, luteolin, and ipolamiide. αSpinasterol has the strongest binding affinity (−8.9
Makara J. Sci.

kcal/mol) followed by apigenin (−8,7 kcal/mol), luteolol7-glucuronide (−8.7 kcal/mol), friedelin (−8.7 kcal/mol),
hispidulin (−8.6 kcal/mol), chlorogenic acid (−8.2
kcal/mol), ipolamiide (−7.3 kcal/mol), geraniol (−5.5
kcal/mol), hentriacontane (−4.3 kcal/mol), and γaminobutyric acid (−4.2 kcal/mol). However, none of the
compounds was higher than oxocarbazate (−11
kcal/mol). The ligand test showed that ASN18, PRO15,
and VAL13 have the same interaction as the reference
ligands. Thus, the most potent inhibitor of cathepsin L
was apigenin. This study showed that S. Jamaicensis
March 2022  Vol. 26  No. 1
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could be used as an inhibitor for Cat L and as a COVID19 drug candidate. Nonetheless, further studies are
needed to support this modeling study through biological
functions exploration in vivo and in vitro using the
SARS-CoV-2 peptide.
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